Prognostic factors of breast phyllodes tumors
Eunah Shin and Ja Seung Koo
Department of Pathology, Yonsei University College of Medicine, Seoul, South Korea
Corresponding Author: Ja Seung Koo, MD, PhD, Department of Pathology, Yonsei University College of Medicine, Severance Hospital, 50 Yonsei-ro, Seodaemun-gu, Seoul 120-752, South Korea. e-mail: kjs1976@yuhs.ac
Summary. Background. Phyllodes tumor (PT) is a relatively rare breast tumor, accounting for <1% of all breast tumors.
Main body. Adjuvant therapy with chemotherapy or radiation therapy, other than surgical excision, has not been established yet. PT, similar to other breast tumors, is classified as benign, borderline, and malignant according to the World Health Organization classification system, depending on stromal cellularity, stromal atypia, mitotic activity, stromal overgrowth, and tumor border. However, this histological grading system cannot effectively or fully reflect the clinical prognosis of PT. Several studies have investigated prognostic factors for PT as some PTs recur or metastasize to distant sites, and thus, prediction of prognosis is clinically imperative.
Conclusion. This review discusses clinico-pathological factors, immunohistochemical markers, and molecular factors that have been investigated in previous studies to have an impact on the clinical prognosis of PT. Histol Histopathol 38, 865-878 (2023)
Key words: Breast, Prognosis, Phyllodes tumor
DOI: 10.14670/HH-18-600
 |
ŠThe Author(s) 2023. Open Access. This article is licensed under a Creative Commons CC-BY International License. |
